Boliven PRO is more than just Clinical Trials

  • Search for throughout all clinical trials
  • Analyze data with charts and graphs, then download your results
  • Share lists of patents with your clients

Search trademarks, companies, patents & more!

Molecular Assessment of Lymph Nodes in Patients With Resected (Stage I to IIIA) Non-small Cell Lung Cancer

Trial Overview

StatusConditionSponsor/Collaborator(s)First ReceivedLast ChangedVerification Date
Completed Lung Cancer University Hospital, Strasbourg, France Other September 13, 2005 August 29, 2011 August 2011

Study TypeStudy DesignPhaseEnrollmentStart DateEnd Date
Observational Observational Model: Case-Only, Time Perspective: Prospective N/A 150 June 2004 -


Service de Chirurgie Thoracique, Hôpital Civil Strasbourg 67091 France - - - -
Service de Pneumologie, Hôpital Lyautey Strasbourg 67091 France - - - -
Service d'Anatomie Pathologique, Hôpital de Hautepierre Strasbourg 67098 France - - - -
Service de Pneumologie, Hôpital de Hautepierre Strasbourg 67098 France - - - -
Laboratoire de Biochimie et de Biologie Moléculaire, Hôpital de Hautepierre Strasbourg 67098 France - - - -

Official Title

Research of Molecular Markers for Diagnosis and/or Prognosis in Lymph Node Metastasis of Resected Non-small Cell Lung Cancer


Genetic: It is a prospective study during two years with three years for follow-up. No
control group is recruited.


GenderMinimum AgeMaximum AgeHealthy Volunteers
Both - N/A No

Inclusion Criteria:

- Patients with resectable non-small cell lung cancer (stage I to IIIA), with a
complete resection of the tumor and paired lymph nodes.

- Informed consent is required.

Exclusion Criteria:

- Another cancer

- Chemotherapy before surgical treatment